ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1638415
Discordance of Diabetic Retinopathy severity in a cohort of Diabetic Nephropathy patients: A Cross-sectional Case-Control Study in a New Mexican population of type 2 Diabetes
Provisionally accepted- 1The University of Oklahoma Health Sciences, Oklahoma City, United States
- 2The University of New Mexico Department of Ophthalmology & Visual Sciences, Albuquerque, United States
- 3New Mexico VA Health Care System, Albuquerque, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Although diabetic retinopathy (DR) and diabetic nephropathy (DN) are well known microvascular complications of diabetes, the correlation between DR and DN remains uncertain. Several studies have suggested differences in etiology and risk factors between these two complications.Objectives: To examine whether diabetic retinopathy (DR) and nephropathy (DN) have significant concordance in terms of severity progression in patients with type 2 diabetes.Methods: A case-control study was conducted involving two cohorts of type 2 diabetic patients from a New Mexican population. The cases had confirmed end-stage renal disease (ESRD; Stage 5, on dialysis, eGFR < 15 mL/min, n = 164), while the controls had mild diabetic nephropathy (DN) (Stage 1 or Stage 2, eGFR > 60 mL/min, n = 165). Systemic parameters were collected through retrospective chart reviews, which included HbA1c, blood pressure (BP), lipid levels, serum creatinine (Cr), and retinopathy status determined by dilated fundus examinations.Statistical analyses were conducted, encompassing univariate and multivariate logistic regression analyses for continuous variables, as well as a Chi-squared test for categorical variables.The majority (65%) of the ESRD cohort had proliferative diabetic retinopathy (PDR), while 18% of patients exhibited no diabetic retinopathy (DR) or mild non-proliferative diabetic retinopathy (NPDR). Conversely, approximately 38% of the mild DN cohort had PDR. In the univariate analysis, ESRD was significantly associated with lower HbA1c levels (p<0.0001) and higher systolic blood pressure (p<0.0001). Within the ESRD cohort, the onset of PDR was significantly linked to younger age (p=0.0002), higher diastolic blood pressure (p=0.0319), and elevated LDL (p=0.0361). In the multivariate analysis, the development of PDR was inversely related to age (p=0.001, OR=0.95) and positively correlated with serum creatinine (p<0.0001, OR=1.25), systolic blood pressure (p=0.0221, OR=1.023), and albuminuria (p=0.0006, OR=4.65). HbA1c levels showed no significant correlation with the progression of PDR. The use of PDR as a screening tool for chronic kidney disease (CKD) has a sensitivity of 78.68% and a specificity of 51.16%, indicating that it is a suboptimal screening method.Conclusions: Our findings suggest discordance between the progression of diabetic retinopathy and nephropathy.
Keywords: Diabetes Mellitus, Diabetic retinopathy (DR), Proliferative diabetic retinopathy (PDR), Glycated hemoglobin (HbA1c), Diabetic Nephropathy (DN), End stage renal disease
Received: 30 May 2025; Accepted: 16 Jul 2025.
Copyright: Ā© 2025 Fitzgerald, Das, Moezzi, Salazar, Mankad, Qualls, Cabrera, Kathuria, Monickaraj, Tzamaloukas and Das. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Arup Das, The University of New Mexico Department of Ophthalmology & Visual Sciences, Albuquerque, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.